HealthMore in Health→
Stem Cell Heart Failure Trial Shows Gains and Risks
Key Takeaways
- A 20-patient randomized trial paired bypass surgery with or without hiPSC-derived cardiomyocyte injections.
- No sustained ventricular tachycardia or tumorigenicity was observed over the primary safety follow-up.
- All treated patients developed early accelerated idioventricular rhythm, and two had significant ventricular tachycardia.
- Secondary analyses showed stronger gains in walk distance, myocardial perfusion, and wall thickening than surgery alone.
DE
DT Editorial Team··via nature.com
